Inactive Instrument

Paratek Pharmaceuticals, Inc.

PRTK

US6993743029

Paratek Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 09, 2023 at 04:08 pm EDT

Paratek Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported revenue was USD 31.24 million compared to USD 24.86 million a year ago. Net loss was USD 20.14 million compared to USD 17.91 million a year ago.

Basic loss per share from continuing operations was USD 0.35 compared to USD 0.35 a year ago. Diluted loss per share from continuing operations was USD 0.35 compared to USD 0.35 a year ago.

Latest news about Paratek Pharmaceuticals, Inc.

Paratek Pharmaceuticals Announces Positive Efficacy Data for Nuzyra® as Post-Exposure Prophylaxis of Inhalational Anthrax, Triggering Additional Procurement Under Barda Project Bioshield Contract	Mar. 05	CI
Paratek Pharmaceuticals, Inc. Promotes Jonathan Light to General Counsel, Corporate Secretary and Chief Compliance Officer	Jan. 16	CI
Paratek Pharmaceuticals, Inc. Promotes Christopher Bostrom to Chief Financial Officer	Jan. 16	CI
Novo Holdings, Gurnet Point Close $462 Million Purchase of Paratek Pharmaceuticals	23-09-22	MT
Novo Holdings closes $462 million acquisition of Paratek Pharmaceuticals	23-09-21	RE
Paratek Pharmaceuticals, Inc. Announces Board Changes	23-09-21	CI
Paratek Pharmaceuticals, Inc.(NasdaqGM:PRTK) dropped from NASDAQ Composite Index	23-09-21	CI
Paratek Pharmaceuticals, Inc.(NasdaqGM:PRTK) dropped from S&P Global BMI Index	23-09-21	CI
Paratek Pharmaceuticals, Inc.(NasdaqGM:PRTK) dropped from S&P TMI Index	23-09-21	CI
Gurnet Point Capital Limited and Novo Holdings A/S acquired acquire Paratek Pharmaceuticals, Inc. from a group of shareholders.	23-09-20	CI
Paratek Pharmaceuticals Says Shareholders Approved $462 Million Acquisition by Gurnet Point Capital, Novo Holdings	23-09-18	MT
Paratek Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Earnings Flash (PRTK) PARATEK PHARMACEUTICALS Reports Q2 Revenue $40M	23-08-03	MT
Paratek Pharmaceuticals' Investor NexPoint Sends Demand Letter for Records of Proposed Takeover by Gurnet	23-07-11	MT
Declaration of Voting Results by Paratek Pharmaceuticals	23-07-11	CI
Paratek Modifies Contract With US Government's BARDA to Advance Nuzyra Antibiotic	23-07-10	MT
Paratek Pharmaceuticals, Inc. Announces Modification of Barda Contract to Advance the Development of NuzyraÂ®? (Omadacycline) for Post-Exposure Prophylaxis and Treatment of Pulmonary Anthrax	23-07-10	CI
Paratek Pharmaceuticals Says 'Disagrees' With NexPoint Asset Management's Accusations	23-06-27	MT
Paratek Pharmaceuticals Acknowledges Receipt of NexPoint Advisors Letter	23-06-27	CI
Paratek Pharmaceuticals' NUZYRA Therapy for Nontuberculous Mycobacterial Lung Disease Gets EU Positive Opinion	23-06-27	MT
NexPoint Advisors Sends a Letter to Paratek Pharmaceuticals	23-06-27	CI
Paratek Pharmaceuticals, Inc. Presents New Data from NUZYRA®? (omadacycline) and Investigator-Initiated Research Programs at ASM Microbe 2023	23-06-12	CI
North American Morning Briefing : Nasdaq Futures -2-	23-06-08	DJ
HC Wainwright Downgrades Paratek Pharmaceuticals to Neutral From Buy, Price Target is $2.15	23-06-07	MT
Jefferies Downgrades Paratek Pharmaceuticals to Hold From Buy, Adjusts Price Target to $2.15 From $5	23-06-07	MT

Chart Paratek Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its commercial product, NUZYRA (omadacycline), is a once-daily oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia (CABP), and acute skin and skin structure infections (ABSSSI) caused by susceptible pathogens. Its other commercial product SEYSARA (sarecycline), is a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The Sarecycline is a narrow spectrum tetracycline designed specifically for dermatological use. It markets omadacycline in the United States as an empiric monotherapy in the indications of ABSSSI and CABP for patients that have both a known or suspected resistant pathogen and at least one significant comorbidity.

Sector

Pharmaceuticals

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+34.35%	705B
NOVO NORDISK A/S	+29.39%	583B
JOHNSON & JOHNSON	-3.49%	364B
MERCK & CO., INC.	+20.15%	332B
ABBVIE INC.	+6.19%	291B
ASTRAZENECA PLC	+14.11%	238B
ROCHE HOLDING AG	-3.03%	210B
NOVARTIS AG	+10.02%	209B
AMGEN INC.	+9.21%	169B

Other Pharmaceuticals